Contact Information: Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs to Present at 2008 BIO Investor Forum
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - October 21, 2008) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) today
announced that the Company will present at the 2008 BIO Investor Forum in
San Francisco, October 29-31, 2008. The conference will be held at The
Palace Hotel in San Francisco. Management will be available to meet with
investors or licensing partners October 29-30.
Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland
BioLabs, will give a presentation on the Company's lead compounds and
development strategy on October 30, at 2:45 p.m. PT. The presentation will
be broadcast live over the Internet and archived for 90 days. Interested
parties may listen to the presentation by visiting the Investor Information
section of the Company's website at: www.cbiolabs.com.
Cleveland BioLabs is developing a pipeline of products from two primary
families of compounds: Protectans and Curaxins. Protectans are being
developed as drug candidates that protect normal tissues from acute
stresses such as radiation and chemotherapy. Curaxins are being developed
as anticancer agents that could act as mono-therapy drugs or in combination
with other existing anticancer therapies.
The Company has completed a Phase II clinical trial of Curaxin CBLC102 in
advanced, hormone-refractory (androgen independent) prostate cancer.
CBLC102 is an orally administered, small molecule designed to kill tumor
cells through multiple mechanisms of action targeting signaling pathways
frequently deregulated in cancer. Results of the trial are expected to be
reported in the fourth quarter.
Cleveland BioLabs recently announced that the first healthy volunteer was
dosed in the initial human safety study for its lead tissue protection
compound, Protectan CBLB502, which is under development for the treatment
for Acute Radiation Syndrome (ARS). Protectan CBLB502 is being developed
under the FDA's animal efficacy rule to treat radiation injury following
exposure to radiation from nuclear or radiological weapons, or from nuclear
accident. This approval pathway requires demonstration of efficacy in
representative animal models and safety and drug metabolism testing in a
representative sample of healthy human volunteers. The Company has already
established cGMP quality manufacturing for Protectan CBLB502, and
demonstrated pre-clinical activity of this product in animal models of ARS.
Earlier this year, the Biomedical Advanced Research and Development
Authority (BARDA) of the of the Department of Health and Human Services
(DHHS) and the Department of Defense (DoD) awarded Cleveland BioLabs two
development contracts totaling $22.2 million for the advanced development
of Protectan CBLB502, as a radiation countermeasure. These two awards are
expected to support the final stages of Protectan CBLB502's development
necessary for submission for FDA approval.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's periodic filings with the
Securities and Exchange Commission.